Clinical Trial Update: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 open-label study of ABT-199 (venetoclax) in chronic lymphocytic leukemia patients relapsed/refractory after BCR signaling pathway inhibitor therapy; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ABT-199 (GDC-0199) (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-12-19